X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TI-168 is the Company’s next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.
Lead Product(s): TI-168
Therapeutic Area: Genetic Disease Product Name: TI-168
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
The Company intends to use the net proceeds for pipeline development activities including, BX1000, an intermediate duration, clinical stage blocking agent, for neuromuscular blockade (NMB) in patients undergoing elective surgery.
Lead Product(s): BX1000
Therapeutic Area: Neurology Product Name: BX1000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 17, 2023
Details:
The merger adds TeraImmune’s TI-168 asset to the Baudax portfolio, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.
Lead Product(s): TI-168
Therapeutic Area: Genetic Disease Product Name: TI-168
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: TeraImmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 30, 2023
Details:
BX1000 can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMB dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or another provider.
Lead Product(s): BX1000
Therapeutic Area: Neurology Product Name: BX1000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
The Company intends to use the net proceeds from this offering for pipeline development activities, including BX1000, being developed for neuromuscular blockade (NMB) in patients undergoing elective surgery.
Lead Product(s): BX1000
Therapeutic Area: Neurology Product Name: BX1000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 01, 2023
Details:
The Company intends to use the net proceeds from this offering for pipeline development activities including, Anjeso (meloxicam), a nonsteroidal anti-inflammatory drug (NSAID) to treat symptoms of Osteoarthritis, Rheumatoid Arthritis, and Moderate-to-Severe Pain.
Lead Product(s): Meloxicam
Therapeutic Area: Neurology Product Name: Anjeso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 26, 2023
Details:
BX1000 can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMB dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or another provider.
Lead Product(s): BX1000
Therapeutic Area: Neurology Product Name: BX1000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
BX1000 can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMB dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or another provider.
Lead Product(s): BX1000
Therapeutic Area: Neurology Product Name: BX1000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
BX1000 can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMB dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or another provider.
Lead Product(s): BX1000
Therapeutic Area: Neurology Product Name: BX1000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.
Lead Product(s): TI-168
Therapeutic Area: Genetic Disease Product Name: TI-168
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
